Cargando…

Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life

The introduction of direct-acting antiviral agents (DAAs) into clinical practice has revolutionized the therapeutic approach to patients with chronic hepatitis C virus (HCV) infection. According to the most recent guidelines, the first line of treatment for HCV infection involves the use of one of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pugliese, Nicola, Polverini, Davide, Arcari, Ivan, De Nicola, Stella, Colapietro, Francesca, Masetti, Chiara, Ormas, Monica, Ceriani, Roberto, Lleo, Ana, Aghemo, Alessio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674442/ https://www.ncbi.nlm.nih.gov/pubmed/37999621 http://dx.doi.org/10.3390/tropicalmed8110502

Ejemplares similares

Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization
por: Masetti, Chiara, et al.
Publicado: (2022)

Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges
por: Pugliese, Nicola, et al.
Publicado: (2022)

Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients
por: Colapietro, Francesca, et al.
Publicado: (2023)

Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations
por: Vespa, Edoardo, et al.
Publicado: (2021)

What do clinicians need to watch for with direct‐acting antiviral therapy?
por: Aghemo, Alessio, et al.
Publicado: (2018)

Correction: Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma
por: Lanza, Ezio, et al.
Publicado: (2020)

Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma
por: Lanza, Ezio, et al.
Publicado: (2020)

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2019)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center
por: Lleo, Ana, et al.
Publicado: (2021)

Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure
por: Mohammed Abdul, Mubeen Khan, et al.
Publicado: (2020)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?
por: Solitano, Virginia, et al.
Publicado: (2021)

Role of liver biopsy in hepatocellular carcinoma
por: Di Tommaso, Luca, et al.
Publicado: (2019)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Liver tests abnormalities in COVID-19: trick or treat?
por: Vespa, Edoardo, et al.
Publicado: (2020)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals
por: Guo, Qianyu, et al.
Publicado: (2022)

Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection
por: Aghemo, Alessio, et al.
Publicado: (2012)

Management of patients with autoimmune liver disease during COVID-19 pandemic
por: Lleo, Ana, et al.
Publicado: (2020)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
por: Rockstroh, Jürgen K, et al.
Publicado: (2013)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
por: Mathur, Poonam, et al.
Publicado: (2018)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Changing Population of Liver Transplant Recipients in the Era of Direct-acting Antiviral Therapy
por: Xie, Chencheng, et al.
Publicado: (2020)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)

Antimitochondrial Antibodies: from Bench to Bedside
por: Colapietro, Francesca, et al.
Publicado: (2021)

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
por: Kieran, Jennifer Ann, et al.
Publicado: (2015)

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
por: Comarmond, Cloé, et al.
Publicado: (2020)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
por: Pabjan, Paweł, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_licjrojqqaf96ecgeilougb23e